Rajeev Dadoo Buys Shares in ARS Pharmaceuticals
Rajeev Dadoo purchased 30,000 shares of ARS Pharmaceuticals, Inc. on June 24.
Key Points
- Rajeev Dadoo bought 30,000 shares of ARS Pharmaceuticals on June 24, 2026, as part of an insider transaction.
- Shares of ARS Pharmaceuticals traded near $8.54 on the NasdaqGM with a market cap of $796.4 million.
- Analysts have a strong buy consensus on ARS Pharmaceuticals, with a mean target price of $28.4.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Rajeev Dadoo, an insider at ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY), recently bought 30,000 shares of the company. This transaction took place on June 24, 2026, but no specific price or total value was disclosed.
Insider Buying and Selling at ARS Pharmaceuticals, Inc.
On June 24, Rajeev Dadoo acquired 30,000 shares of ARS Pharmaceuticals. This transaction was not part of a pre-planned trading program. In other insider activity, Eric Karas, Chief Commercial Officer, sold 25,000 shares at $10.00 each on June 12 under a Rule 10b5-1 plan. On the same day, he also bought 25,000 shares at $1.50.
ARS Pharmaceuticals, Inc. Stock Up 45.0%
Shares of ARS Pharmaceuticals traded near $8.54 on Saturday. The company has a market capitalization of approximately $796.4 million. It operates with a beta of 0.826, indicating lower volatility compared to the market. The stock's 52-week range is between $6.66 and $18.90, with a 50-day moving average of $8.69 and a 200-day moving average of $9.37. The company's financial health is supported by a current ratio of 4.943 and a quick ratio of 4.645, though it has a high debt-to-equity ratio of 279.238.
$SPRY stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 25, 2026, Leerink Partners maintained its buy rating on ARS Pharmaceuticals, setting a price target of $24.0. Cantor Fitzgerald previously maintained a buy rating with a target of $30.0 on May 28, 2026. Overall, analysts have a strong buy consensus for the stock, with a mean target price of $28.4 based on five analyst opinions.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California. The company focuses on developing and commercializing treatments for severe allergic reactions. Its lead product, neffy, is a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Founded in 2015, ARS Pharmaceuticals is led by CEO Richard E. Lowenthal and employs 154 people.
Bottom Line
Insider buying can signal confidence in a company's prospects, and Rajeev Dadoo's recent purchase of ARS Pharmaceuticals shares is noteworthy. Investors often track such insider activities for insights into a company's future. However, it's important to remember that this information comes from a 13F filing and may not reflect the current position. Analysts' strong buy ratings and price targets suggest optimism about ARS Pharmaceuticals' potential.
Get ARS Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SPRY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.